Rethinking the Menopause Hormone Therapy Question: Why 'Can I Take HRT?' Is the Wrong Starting Point
Key Insights
The binary "Can I take HRT?" question often shuts women out of care, when the real question should be about individualized risks and benefits.
Transdermal estrogen does not carry the same clotting risk as oral formulations, opening options even for women with prior blood clots or clotting disorders.
Estrogen and progesterone do not cause breast cancer (search) but can accelerate existing hormone-receptor-positive tumors—a distinction critical to informed decision-making.
The conversation around menopause hormone therapy has reached a fever pitch—on social media, in telehealth marketing, and in new books and podcasts. Yet for many women, the question they bring to their doctors remains a binary one: "Can I take HRT?" According to Dr. Lucy McBride, a board-certified internal medicine physician and author, that framing is keeping countless women from the care they need.
"The trouble starts with the question," McBride writes. "We've trained women—and, frankly, a lot of doctors—to ask 'Can I take HRT?' as if hormone therapy were a single locked room you're either let into or kept out of. That's not how this works."
The real question, she argues, is narrower and answerable: "What are the specific risks and benefits of hormone therapy for me?"
The Risks on Both Sides of the Decision
Risk, McBride emphasizes, sits on both sides of the decision. There are risks to taking hormones, but there are also risks to not taking them: bone loss, cardiovascular disease, and the toll on sleep, cognition, and sexual function that estrogen's absence can bring. "'No' is not necessarily the safer answer; 'no' just offers a different set of risks," she notes.
This perspective is echoed by Dr. Mara Gordon, a family physician in Camden, N.J., who writes that the pendulum has swung on hormone therapy. After the Women's Health Initiative study was halted early in the early 2000s due to signals of increased heart disease, breast cancer (search), stroke, and pulmonary embolism (search) risk, prescriptions plummeted. By 2010, researchers estimated that only around 5% of American women over 40 were receiving menopausal hormone therapy (search), down from 22% in 1999-2000.
But reanalysis of that data has shifted the consensus: menopausal hormone therapy (search) is much safer than previously thought for women in their late 40s and 50s.
Transdermal Delivery: A Critical Distinction
One of the most clinically significant distinctions in the risk-benefit calculus involves the route of administration. McBride describes a patient with a genetic clotting disorder and a history of both deep vein thrombosis (search) and pulmonary embolism (search)—exactly the type of patient who typically receives a fast "absolutely not" to hormone therapy.
"While oral estrogen does raise the risk of clots—it passes through the liver, which ramps up clotting factors—estrogen absorbed through the skin, in the form of a patch or a gel, doesn't appear to carry that same risk," McBride explains. "The evidence on this has been consistent for years, including in women with clotting mutations and even a prior clot."
Gordon confirms this finding: "Research generally shows that transdermal estrogen—delivered through a patch—is less likely to cause blood clots than oral estrogen."
Breast Cancer (search): Precision Matters
Nowhere is the need for precise language more critical than with breast cancer (search). "Estrogen and progesterone do not cause breast cancer," McBride states. "What they can do is accelerate the growth of a tumor that already carries receptors for them on its cells. That distinction is real and it matters."
She describes a BRCA-positive patient who chose prophylactic mastectomy and oophorectomy, reducing her breast cancer (search) risk to near zero, and now takes hormone therapy to address bone loss, heart disease, and sexual dysfunction risks. Another patient, five years out from estrogen-receptor-positive breast cancer, made an informed decision with her oncologist to use hormone therapy, prioritizing quality of life.
Gordon advises that a family history of breast cancer (search) does not automatically preclude hormone therapy, but warrants a formal breast cancer risk assessment and consideration of genetic testing. In such cases, professional prescribing guidelines suggest using the minimum effective dose for the shortest possible duration.
What Hormone Therapy Can—and Cannot—Do
The primary indication for systemic hormone therapy remains the treatment of vasomotor symptoms (search)—hot flashes and night sweats—which researchers estimate affect up to 80% of women during the menopausal transition. Systemic hormone therapy also helps prevent fractures in those at high risk of osteoporosis (search), though most organizations do not recommend it solely for this purpose.
However, both physicians caution against the over-promises circulating online. "Hormone therapy is being over-evangelized in the public square," McBride warns. "It is not a cure-all. It will not protect every brain or every heart or reverse aging, regardless of what your social media feed implies."
Gordon reinforces this: "Most major medical organizations—including the U.S. Preventive Services Task Force (search), the American College of Obstetricians and Gynecologists (search), and the Menopause Society (search)—do not recommend hormone therapy for longevity, heart health, or preventing chronic conditions, based on the data currently available."
Dr. Karen Adams, a professor of obstetrics and gynecology at Stanford (search) and director of the Program in Menopause and Healthy Aging, describes the cardiovascular question as "really an unanswered question right now." While some research suggests hormone therapy taken before age 60 or within 10 years of menopause might help prevent atherosclerosis, other studies show no cardiovascular benefit or even increased risk, particularly when initiated after age 60.
"I don't say, 'Here, take hormone therapy. It's going to keep you from having a heart attack,'" Adams says. "We don't have that data. And I don't make that promise."
Non-Hormonal Alternatives
For women who cannot or choose not to use hormone therapy, alternatives exist. Gordon notes that certain antidepressants can reduce hot flash frequency and severity, and fezolinetant, approved by the FDA in 2023, offers another option. Weight-bearing exercise remains one of the most effective tools for preventing osteoporosis (search). McBride adds cognitive behavioral therapy, dietary changes, and lifestyle interventions to the list of genuinely helpful non-hormonal approaches.
The Bottom Line: Conversation Over Prohibition
Both physicians converge on a central point: the decision belongs to the patient, armed with accurate information. "What's been withheld from women isn't the drug but the conversation," McBride writes. "Health has always been a matter of trade-offs, and the person who has to live inside those trade-offs is the patient, not the doctor across the desk."
Dr. Jessica Platt, a family physician in Massachusetts focused on women's health and menopause care, puts it succinctly: "I lay out the risks and benefits. Giving people knowledge and also giving them patient autonomy."
The fix, McBride concludes, isn't a new drug. "It's a better question—asked by the patient and answered by someone who understands the data—and you."